Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoadjuvant Operable Breast Cancer × Epirubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 75 Triple Negative Breast Neoplasms 14 Stomach Neoplasms 12 Inflammatory Breast Neoplasms 11 Esophageal Neoplasms 6 Lymphoma, Large B-Cell, Diffuse 5 Testicular Neoplasms 3 Lymphoma 3 Urinary Bladder Neoplasms 2 Sarcoma 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Lymphoma, B-Cell, Marginal Zone 2 Carcinoma, Hepatocellular 2 Adenocarcinoma Of Esophagus 2 Women With Primary Breast Cancer 1 Upper Tract Urothelial Carcinoma 1 Thymoma 1 Testicular Germ Cell Tumor 1 Small Cell Lung Cancer Extensive Stage 1 Rare Tumour 1 Prostatic Neoplasms 1 Primary Breast Cancer 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Non-Muscle Invasive Bladder Neoplasms 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasm Micrometastasis 1 Neoplasm Metastasis 1

Interventions

palbociclib 1 Letrozole 1 Fluorouracil 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02400567 2022-03-15

NeoPAL

UNICANCER

Phase 2 Completed

Neoadjuvant Operable Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡